InsidersTradesSigma
Follow the ARDELYX INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €983.7m. The latest transaction was reported on 15 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MICHAEL RAAB. The full history is free.
Analysts rate ARDELYX INC Strong Buy (bullish), based on 10 analysts. Average price target: US$12.90.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
ARDELYX INC es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades gastrointestinales y renales.